Ho Rala Phetoho ea GLP-1 Peptide le Phallo ea Mosebetsi bakeng sa Mananeo a Phetolelo
Phethahatso Overview: Phephetso ea Phetolelo ho Boenjiniere ba Incretin
Glucagon-joaloka peptide-1 (GLP-1) li-receptor agonists le li-agonists tse peli / tse tharo tsa incretin (GLP-1/GIP/Glucagon) e emela e 'ngoe ea lihlopha tsa kalafo tse fetolang ka ho fetesisa tsa lefu la metabolism, botenya, le mafu a neurodegenerative. Leha ho le joalo, ho fetolela tatellano ea mofuta o hlaha oa GLP-1 ho motho ea sebetsang oa lithethefatsi ho hlahisa mathata a matla a lik'hemik'hale le a biophysical.. Native GLP-1 (7-36) amide e bonts'a phela plasma halofo ea bophelo ($t_{1/2}$) ea ka tlase ho 2 metsotso ka lebaka la proteolysis e potlakileng ka Dipeptidyl Peptidase-4 (DPP-IV) at the $\text{Ala}^8-\text{Glu}^9$ peptide bond, e kopantsoe le ho tlosoa ha renal ($NMWCO \approx 30-50\text{ kDa}$).
Ho fihlella dosing ea kliniki hanngoe ka beke kapa hanngoe ka khoeli, mananeo a phetolelo a tlameha ho kenyelletsa liphetoho tse rarahaneng tsa lik'hemik'hale - ho kenyeletsoa le li-amino acid tseo e seng tsa tlhaho tse thibetsoeng., side-chain fatty acid acylation (lipidation), Sebaka se ikhethileng Poly(ethylene glycol) (PEGylation), le li-labeling tsa tlhahlobo ea mali. Leha ho le joalo, likhetho tsa pele tse entsoeng nakong ea ho sibolloa-mohato o tiileng oa peptide synthesis (SPSS) hangata ho theha mekhoa e matla ea ho hloleha nakong ea ho phahamisa:
- Kopanyo & Gelation: Hydrophobic fatty acid side chains or polydisperse PEG polymers drive intermolecular $\beta$-sheet self-assembly during cleavage and purification.
- Litšila tsa Diastereomeric: Ho kopanya mehato e mengata ea tharollo ea li-lipophilic linkers ho eketsa lebelo la morabe litsing tsa chiral.
- Analytical Masking: Khokahano ea li-peptide tsa ho hlakoloa tse amanang haufi-ufi ($n-1, n-2$) le mefuta ea ho senyeha ha ketane ea isobaric ($D\text{-Asp}$, $\beta\text{-Asp}$) nakong ea Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC).
- Tshebetso Non-linearity: Ho eketseha ho tloha ho palo ea lipatlisiso tsa milligram ho ea ho tlhahiso ea lifofane tsa multigram le kilogram ho lebisa ho se nang moeli oa boima ba chromatographic le ho hlōleha ha mocheso..
Moralo ona o hlalosa mokhoa oa boenjineri oa ho qetela ho isa pheletsong o hokahanyang likhetho tsa tatellano ea tatellano ea maemo a pele ka kotloloho le sekhahla sa ho theosa., netefatso ya tshekatsheko, likhetho tse hlahang tsa tlhahiso joalo ka khatiso ea 3D e lokiselitsoeng ke GMP, le boikamahanyo ba taolo ba ICH.
Sethala 1 - Phetoho ea Tatelano ea Pele & Half-Life Extension Chemistries
Ho rala pheko ea phetolelo ea GLP-1 ho hloka leano la phetoho ea lik'hemik'hale tse nang le mekhahlelo e mengata ho thibela ka nako e ts'oanang ho thibela enzymatic cleavage., ho tlosoa butle ha renal, le ho boloka kinetics e tlamang li-receptor ($EC_{50}$).
[Native GLP-1 (7-36)] : H2N-His7-Ala8-Glu9-Gly10-Thr11-Phe12-Thr13-Ser14-Asp15-Val16...-Lys26...-Lys34-Gly37-OH
|
(DPP-IV Cleavage Point)
[Engineered Analog] : H2N-His7-[Aib8]-Glu9-Gly10-Thr11-Phe12-Thr13-Ser14-Asp15-Val16...-[Lys26(Spacer-FattyAcid)]...-[Arg34]-Gly37-NH2
| |
(Protease Resistant) (Albumin Binding Handle)
1. Ho tsitsisa ha Enzymatic: Khanyetso ea DPP-IV
Substituting the native $\text{Ala}^8$ residue with $\alpha$-aminoisobutyric acid ($\mongolo{Aib}^8$) or $D\text{-Ala}^8$ e hlahisa tšitiso e matla ho potoloha sebaka sa $N$-terminal catalytic cleavage ntle le ho senya alpha-helical docking sebakeng sa GLP-1 receptor extracellular.
Sekhahla sa ho senyeha ha kamehla ($k_{katse}/K_m$) bakeng sa DPP-IV enzymatic cleavage e fokotsehile ho latela taelo ea pele ea Michaelis-Menten kinetics.:
$$v = \frac{V_{max} [S]}{K_m \left(1 + \frac{[I]}{K_i}\hantle) + [S]}$$
Where substitution with $\text{Aib}^8$ e eketsa tšitiso ea matla ea ho kenya tšebetsong sebaka ($\Delta G^\ddagger$), ho etsa hore sekhahla sa cleavage se nyatsehe ($k_{obs} < 10^{-6}\mongolo{ s}^{-1}$).
2. Lipidation Chemistry: Khahlano le C16. C18 Diacid Architecture
Covalent conjugation ea liketane tse nang le mafura a mafura a khothalletsang tlamo e khutlisetsoang ho Human Serum Albumin (HSA, $K_d \sim 10-50\text{ }\mu\text{M}$), ho fokotsa ho hloekisoa ha renal le ho sireletsa mokokotlo oa peptide ho li-endopeptidase tseo e seng tse khethehileng..
Ho latela lipatlisiso tse hatisitsoeng ho Nahana hape ka li-peptide ka Lipidation Half-Life Extension Kinetics, phetoho ho tloha ho C16 palmitoyl mono-acid (Mehaho ea Liraglutide, $t_{1/2} \sim 13\text{ h}$) to a C18 octadecanedioic acid diacid via a flexible $\gamma\text{-Glu-OEG}_2$ sepakapaka ($\gamma\text{-L-glutamyl-(\beta-alanyl-2,2′-(ethylenedioxy)bis(ethylamine))}$, Mehaho ea Semaglutide) extends human plasma half-life to $\sim 165\text{ lihora}$.
Lys26 Side Chain ($\epsilon$-amine)
|
(NH-CO-CH2)
|
[$\gamma$-Glu Spacer]
|
[OEG Linker 1: 8-amino-3,6-dioxaoctanoic acid]
|
[OEG Linker 2: 8-amino-3,6-dioxaoctanoic acid]
|
[Octadecanedioic Acid: HOOC-(CH2)16-CO-]
3. Lik'hemik'hale tse khethehileng tsa sebaka sa PEGylation
Bakeng sa pokello e seng ea covalent kapa nako e telele ea sistimi, monodisperse kapa polydisperse Poly(ethylene glycol) (PEG, 20-40 kDa) e kopanngoa ka li-handles tse khethehileng tsa bio-orthogonal:
- Thiol-Maleimide Ligation: Reaction of an engineered $Cys$ residue with Maleimide-PEG at $\text{pH } 6.5 - 7.2$.
- Oxime Ligation: Reaction of an aminooxy-functionalized PEG with an $N$-terminal aldehyde or keto-amino acid at $\text{pH } 4.5 - 5.5$.
Joalokaha ho ngotsoe ho Lithuto tsa ACS Bioconjugate Chemistry ka PEGylation ea Sebaka sa Sebaka, PEGylation e holisa radius ea hydrodynamic haholo ($R_h$), e baloa ka Polymer Scaling Law:
$$R_h = K_{PEG} \cdot (M_w)^a$$
Where $M_w$ is the PEG molecular weight and $a \approx 0.55-0.60$ libakeng tse nang le metsi a mangata. Le ha PEGylation e thibela ho sefa ha glomerular ka nepo, e ka fokotsa matla a ho kenya li-receptor ka lebaka la tšireletso e matla, e hlokang bolelele ba lihokelo tse hlophisitsoeng hantle.
4. Tlhahlobo & Analytical Labeling Handles
Lithuto tsa pele tsa phetolelo li hloka ADME e ngata, kabo ya dithishu, le sebopeho se kopanyang lisele. Lihlopha tse kenyelletsang tsa baqolotsi ba litaba li tlameha ho etsoa ka mokhoa o hlophisitsoeng ho qoba ho kena-kenana le kamano ea GLP-1R.:
- Li-tag tsa Fluorescent: FITC kapa Cyanine5.5 (Cy5.5) e kopantsoe ka khetho ea Lysine acylation kapa Thiol-alkylation.
- Li-Labels tsa Isotopic: Uniform $^{13}\mongolo{C}/^{15}\mongolo{N}$ Li-amino acid tse tsitsitseng tsa isotope tse kentsoeng ka har'a tatellano ea mantlha ea hydrophobic bakeng sa quantification e felletseng ea LC-MS/MS (Mefuta ea MRM/PRM) ka matrix a plasma ea preclinical.
Leano la ASCII 1: Tšireletso ea Orthogonal & Ho Kopanya ha Ketane ka Mahlakoreng
To achieve site-specific acylation at $\text{Lys}^{26}$ while leaving $\text{Lys}^{34}$ (or $\alpha\text{-NH}_2$) e sa tshoaroeng, sekema sa tshireletso ya orthogonal se tlamehile:
Fmoc-Lys(Mtt)-OH or Fmoc-Lys(Alloc)-OH at Position 26
|
[Assembly of Core Peptide Chain on Resin via SPPS]
|
Selective De-protection of Mtt (1% TFA/DCM) or Alloc (Pd(PPh3)4/PhSiH3)
|
Solid-Phase Coupling: Fmoc-OEG-OH -> Fmoc-OEG-OH -> Fmoc-Glu-OtBu -> Mono-tert-butyl octadecanedioate
|
Global Deprotection & Resin Cleavage (TFA / TIS / H2O / EDT = 92.5 : 2.5 : 2.5 : 2.5)
Bakeng sa lihlopha tse hlahlobang tatellano e rarahaneng ea liphetoho tse ngata, ho sebelisa chelete e hlophisitsoeng sethaleng se tloaelehileng sa peptide synthesis e nang le bokhoni ba ts'ireletso ea orthogonal e netefatsa bohloeki bo phahameng ba pele pele ho nyoloha.
Sethala 2 - Tharollo-Phase Bioconjugation & Reaction Engineering
Ho rarolla mathata a Qeto Matrix: Racemization & Taolo e Fetang-Acylation
Nakong ea ho eketseha ha bioconjugation ea lipophilic linkers (mohlala, C18 diacids with $\gamma\text{-Glu-OEG}_2$ li-spacers), li-parameter tse sa nepahalang li baka liprofaele tse itseng tsa litšila:
BIOCONJUGATION TROUBLESHOOTING FLOWCHART
|
+--------------------------------+--------------------------------+
| |
v v
[Symptom: Over-Acylation Impurity] [Symptom: Racemization at Chiral Linker]
(Nα,Nε-bis-acylated product > 1.5%) (D-Glu / D-Lys diastereomer species > 0.5%)
| |
+---> Root Cause: pH > 8.8 (N-terminal +---> Root Cause: Excess base / High Temp
| α-amine becomes unprotonated) | during activated ester coupling
| |
+---> Action: Implement automated +---> Action: Switch from HATU to Oxyma Pure/DIC;
pH-stat titration at pH 8.2-8.5 maintain reaction temperature at 18°C–20°C
| Mokhoa oa ho hloleha / Ho se hloeke | Sesosa sa ho qala | Letšoao la Tlhahlobo | Leano la ho Fokotsa Ts'ebetso |
|---|---|---|---|
| $N^\alpha,N^\epsilon$-Bis-Acylation | Reaction $\text{pH} > 8.8$ kapa acylating agent e feteletseng. ($>1.5\mongolo{ equiv.}$) | UHPLC tlhoro e kopanyang tlhoro ea kamora-kholo ($+M_{lipid}$ Ho fetoha ha MW ho MS) | Tighten $\text{pH}$ laola ho $8.2-8.5$; moeli oa stoich. to $1.05-1.15\text{ equiv.}$; sebelisa pH-stat automated titration |
| Diastereomeric Racemization ($D\text{-Glu}$) | Linako tse atolositsoeng tsa karabelo ka motheo o matla (mohlala, DIPEA) ka $>25^\circ\text{C}$ | Chiral LC-MS or Marfey’s method showing $D\text{-amino acid} > 0.2%$ | Kenya sebaka sa DIPEA ka $N$-methylmorpholine; lower coupling temp to $18-20^\circ\text{C}$; amohela Oxyma Pure / DIC |
| Lipid Ester Hydrolysis / Tlokotsi | Aqueous buffer ratio e phahame haholo ($>40%\mongolo{ H}_2mongolo{O}$) ho baka ester hydrolysis | MS peak e ts'oanang le selelekela sa hydrolyzed diacid | Optimize solvent ratio to $\text{DMF/Metsi } 80:20\mongolo{ v/v}$ kapa $text{NMP/DMSO}$; thibela ts'ebetso ea metsi |
Le hoja liphetoho tse nyenyane li ka tsamaisoa ka-resin, tlhahiso e kholo hangata e laela mokhoa oa lebasetere: ho kopanya mokokotlo oa peptide holim'a resin, e lateloe ke kopano ea post-cleavage solution-phase ea li-lipid linkers tse turang kapa li-polymers tsa PEG ho fokotsa litšila tse tala..
+-----------------------------------------------------------------------------------+
| SOLUTION-PHASE BIOCONJUGATION PARAMETERS |
+--------------------------+--------------------------------------------------------+
| Parameter | Optimal Process Window |
+--------------------------+--------------------------------------------------------+
| Peptide Concentration | 5.0 - 15.0 mM |
| Acylating Agent Stoich. | 1.05 - 1.25 equiv. relative to target Lys |
| Solvent System | DMF / Water (70:30 v/v) or NMP / DMSO mixtures |
| Reaction pH | 8.2 - 8.5 (controlled via N-methylmorpholine or TEA) |
| Reaction Temperature | 18°C - 22°C |
| Coupling Reagents | PyBOP / Oxyma Pure or HATU / HOAt |
+--------------------------+--------------------------------------------------------+
Chemoselectivity & $pK_a$ Taolo
Selective acylation of the $\epsilon\text{-amino}$ group of $\text{Lys}^{26}$ ($pK_a \approx 10.5$) over the $N$-terminal $\alpha\text{-amino}$ sehlopha ($pK_a \approx 8.0$) e hloka tlhokomelo e nepahetseng ea buffer pH. Operating within a narrow window of $\text{pH } 8.2 - 8.5$ maintains the $\alpha\text{-amine}$ sebakeng se nang le protoned haholo ($\mongolo{-NH}_3^+$), while allowing sufficient unprotonated nucleophilic $\epsilon\text{-amine}$ ($\mongolo{-NH}_2$) ho arabela ka NHS-esters e sebetsang kapa tetrafluorophenyl (TFP) esters.
Sekhahla sa karabelo ea tatellano ea bobeli khafetsa ($k_{obs}$) bakeng sa bioconjugation e khethiloeng e laoloa ke:
$$\frac{d[\mongolo{Kopanya}]}{dt} = k_0 \cdot \left(\frac{1}{1 + 10^{(pK_a – \text{pH})}}\hantle) [\mongolo{Peptide}] [\mongolo{Moemeli oa Acylating}]$$
Ho tsamaisa karabelo ea bioconjugation ka har'a a bioconjugation e khethehileng le phetoho suite e nang le li-loops tse ikemetseng tsa pH-stat li felisa lihlahisoa tse lehlakoreng tse fetang acylation ($N\alpha,N\epsilon\text{-bis-acylated}$ mefuta).
Sethala 3 - Ts'ebetso ea likarolo tsa Scale-Up: SPPS ho SPPS-LPPS Hybrid Synthesis
Ho eketsa tlhahiso ea GLP-1 ho tsoa ho bongata ba benche ea laboratori (0.1–1.0 g) ho li-batches tsa lifofane tsa kilogram li hlahisa mefokolo ea boenjiniere ba thermodynamic le 'mele.
[LAB SCALE: Pure SPPS] [PILOT/COMMERCIAL SCALE: Hybrid SPPS-LPPS]
0.1 - 100 g Batch Capacity 1.0 kg - 100 kg Batch Capacity
- High DMF/NMP consumption (>1000 L/kg) - Slashes solvent consumption by 60%
- Crude purity drops on long sequences - Fragment purity >95% prior to condensation
- Resin swelling & pressure drop limits - Controlled solution-phase thermodynamics
1. Solid-Phase vs. Mokelikeli-Mokhahlelo oa Sekhechana sa Koaso
Linear SPPS ea 30–40 mer GLP-1 analogues e ba le pokello e hlakileng ea litšila tse fokotsang ($n-1, n-2$) ka lebaka la ho kopanya steric betheng ea resin. Joalo ka ha ho hlalositsoe ho Tlhahlobo ea Setsi sa Tsebo sa Bachem mabapi le Scale-Up ea Industrial SPPS, kakaretso ea lihlahisoa tse tala li theoha ka tlase $20%$ sekala haeba se sebetsoa ka mokhoa o hlakileng.
Ho hlola sena, mananeo a kajeno a phetolelo a amohela SPPS-LPPS Hybrid Fragment Condensation, joalo ka ha ho totobalitsoe ke Lengolo la PDA ho Hybrid SPPS-LPPS Fragment Condensation.
Likaroloana tse khutšoane tsa peptide tse sirelelitsoeng (mohlala, Sekhechana sa A: mesaletsa 7-14; Karolo ea B: mesaletsa ea 15-26; Karolo ea C: masalla 27-37) li entsoe ka thoko ho resin ea 2-chlorotrityl chloride, e petsohileng tlasa maemo a asiti e bobebe ($0.5-1.0%\mongolo{ TFA}$ ho DCM) ho baballa lihlopha tse sireletsang mahlakoreng, 'me ka mor'a moo li kopantsoe le mokhahlelo oa tharollo:
Fragment A (7-14)-OH + H-Fragment B (15-26)-OtBu
| (Coupling: DIC / Oxyma Pure, DMF/DCM, 20°C)
v
Protected Intermediate AB (7-26)-OtBu
| (Deprotection)
v
H-Intermediate AB (7-26)-OH + H-Fragment C (27-37)-NH2
| (Coupling: PyBOP / HOAt)
v
Full-Length Protected GLP-1 Analog
| (Global Deprotection: TFA Cocktail)
v
Crude GLP-1 Conjugate
Epirical Scale-Up Benchmark: Litekong tsa ho leka-lekanya (1.0-5.0 lik'hilograma tsa batch li matha), ho amohela protocol ena ea 3-fragment ea SPPS-LPPS e lula e fihlela litholoana tsa tharollo ea karolo ea tharollo ea $.> 85%$ e sirelelitsoeng sekhechana purities $> 92%$ pele ho condensation ea ho qetela. Ho feta moo, elevating RP-HPLC column temperatures to $50^\circ\text{C} – 55^\circ\text{C}$ nakong ea tlhoekiso ea ho itokisa ea C4 e rarolla lipophilic back-pressure hysteresis, ho ntlafatsa chai ea ho hlaphoheloa ka $18-22%$ bapisoa le ambient-thempereichara matha.
2. Khromatographic Scale-up & Kholomo Non-linearity
Ho hloekisoa ha li-peptide tse nang le lipidated kapa PEGylated GLP-1 ho itšetlehile ka Reverse-Phase HPLC (RP-HPLC) ho sebelisa likhato tse emisang tsa silika tsa C4 kapa C18 ($100-300\mongolo{ \AA}$ pore boholo, $10\mongolo{ }\mu\text{m}$ boholo ba karoloana).
Nakong ea ntlafatso, bophahamo ba bethe ea kholomo ($L$) le lebelo la mola ($u$) e tlameha ho ts'oaroa ka mokhoa o tsitsitseng ha o ntse o phahamisa bophara ba kholomo ($D$) ho boloka qeto ea chromatographic ($R_s$):
$$\frac{V_1}{V_2} = \left(\frac{D_1}{D_2}\hantle)^2$$
$$R_s = \frac{\sqrt{N}}{4} \letsetsoa(\frac{\alpha - 1}{\alpha}\hantle) \letsetsoa(\frac{k'}{1 + k'}\hantle)$$
CHROMATOGRAPHIC RESOLUTION DYNAMICS
Analytical (4.6 mm ID) Preparative (50 mm ID) Industrial (300-600 mm ID)
[Peak A][Peak B] --> [ Peak A ][ Peak B ] --> [ Peak A ][ Peak B ]
(Sharp separation) (Slight peak broadening) (Mass loading non-linearity)
Liketane tsa hydrophobic lipid li eketsa nako ea ho boloka ($k'$), e hlokang lithempereichara tse phahameng tsa ts'ebetso ($45^\circ\text{C} – 60^\circ\text{C}$) le organic modifier gradients (Isopropanol/Acetonitrile in $0.1%\text{ TFA}$ or $20\text{ mM } \mongolo{NH}_4\text{OAc}$) ho thibela ho senyeha ha kholomo le hysteresis.
Sethala 4 - Boitšoaro ba Tlhahlobo e Phahameng ea Boipheliso & Litaelo tsa Phallo
Katleho ea ho fetolela e hloka netefatso e matla ea tlhahlobo ho netefatsa boitsebiso ba lik'hemik'hale, bohloeki, le ho lokoloha ho tsoa lihlahisoa tsa lehlakore tsa immunogenic.
ESI-HRMS MASS SPECTRUM (MOL Changes CoA Validation)
100| [M+3H]3+ m/z = 1371.6842
| |
50| [M+4H]4+ | [M+2H]2+
| m/z = 1029.0151 | m/z = 2057.0238
0+-------------------------------------------------> m/z
Mekhoa ea Tlhahlobo
- Ultra-High Performance Liquid Chromatography (UHPLC): Method optimized for resolving $D\text{-Glu}$, $D\text{-Ala}$, and $\beta\text{-Asp}$ li-isomer tsa ho hlophisa bocha.
- Electrospray Ionization High-Resolution Mass Spectrometry (ESI-HRMS): Qeto e nepahetseng ea boima ka har'a $< 5\mongolo{ ppm}$ moeli oa phoso ho netefatsa boima ba molek'hule ba monoisotopic.
- Tandem MS/MS Sequencing: Karohano e Bakiloeng ke Ho thulana (CID) kapa Electron-Transfer Dissociation (ETD) ho netefatsa maemo a amanang le lipid/PEG sebakeng se itseng.
Setifikeiti se Feletseng sa Tlhahlobo (CoA) Litlhaloso
Tafole e ka tlase e bonts'a mekhoa ea tokollo ea boemo ba taolo e hlokahalang bakeng sa ho fetolela li-conjugate tsa GLP-1 peptide.:
| Tšobotsi ea Boleng | Mokhoa oa Tlhahlobo ea Tlhahlobo | Mekhoa ea ho Amohela | Lebaka la Saense |
|---|---|---|---|
| Boitsebiso ba Lik'hemik'hale | ESI-HRMS / MALDI-TOF MS | Lipapali tse baloang MW ($\pm 0.05\text{ Le}$) | E netefatsa tatelano ea mantlha ea amino acid le phetoho |
| Bohloeki ba Lik'hemik'hale | RP-HPLC / UHPLC ($214\mongolo{ nm} / 280\mongolo{ nm}$) | $\ge 98.0%$ (Sebaka %) | E fokotsa litšila tsa peptide tse nyenyefalitsoeng le tse nang le oxidized |
| Tšilafalo e le Mong | RP-HPLC / LC-MS | $\the 0.5%$ | E beha moeli ka $n-1$ e le 'ngoe kapa mefuta ea diastereomeric |
| Litšila ka Kakaretso | RP-HPLC | $\the 2.0%$ | E lumellana le litekanyo tsa taolo tsa ICH Q3A |
| Bohloeki ba Stereoisomeric | Chiral GC-MS / Mokhoa oa Marfey | $\le 0.2\text{ D-amino acid}%$ | E thibela tahlehelo ea ts'ebetso ea li-receptor le immunogenicity |
| TFA e setseng | Ion Chromatography (KEA BONA) | $\le 0.5%\text{ w/w}$ (kapa Phapanyetsano ho Acetate/HCl) | TFA e feteletseng e baka cytotoxicity litekong tse thehiloeng liseleng |
| Metsoako e setseng | Chromatography ea Khase (GC-HS) | DMF $< 880\mongolo{ ppm}$, NMP $< 530\mongolo{ ppm}$ | E kopana le Sehlopha sa ICH Q3C 2 meeli ea tšireletso ea solvent |
| Litaba tsa Endotoxin | Tlhahlobo ea LAL Kinetic Chromogenic | $< 0.01\mongolo{ EU/mg}$ | Critical for $in\text{ vivo}$ lithuto tsa pele tsa liphoofolo |
| Ho beleha ha Microbial | Ho Hloekisa Membrane ka ho Otloloha | Feta (Ha ho kholo ho 14 matsatsi) | E netefalitsoe ka Sehlopha 100 ts'ebetso ea kamore e hloekileng |
Ho boloka pepeneneng, CoA e ka lateloang ka botlalo ho tsoa ho molekane ea fanang ka sebopeho se phahameng sa HPLC/MS CoA e felisa litšitiso tsa netefatso pele ho tlhahiso ea IND.
Sethala 5 - Likhetho tse Hlahang tsa Tlhahiso: GMP-Ready 3D Printing & Novel Delivery Systems
Ha a ntse a setso metsi parenterals (liente tsa subcutaneous) e laola mekhoa ea hona joale ea GLP-1, mananeo a phetolelo a sebelisa mekhoa e tsoetseng pele ea tlhahiso-haholo-holo GMP-Ready 3D Printing le Microfluidic Encapsulation-ho notlolla litsela tsa tsamaiso ea molomo le ea depo e bonolo ho mokuli.
GMP-READY 3D PRINTING & FORMULATION PATHWAYS
|
+-------------------------+-------------------------+
| |
v v
[Semi-Solid Extrusion (SSE)] [Subcutaneous Implants]
- Multi-layer gastro-resistant oral tablets - Biodegradable PLGA/PCL matrix
- pH-responsive Eudragit L100-55 coatings - Zero-order sustained release (1-3 months)
- Protects peptide from stomach pepsin/acid - Eliminates peak-to-trough plasma spikes
1. Semi-Solid Extrusion (SSE) 3D Khatiso bakeng sa Phano ea Molomo
Tsamaiso ea molomo ea li-peptide tsa GLP-1 e sitisoa haholo ke ho senyeha ha asiti ea gastric ($\mongolo{pH } 1.5 - 2.0$) le tšilo ea enzymatic ka pepsin le trypsin ka maleng a manyane.
Joalo ka ha ho totobalitsoe ho Patlisiso ea Tlhaho ka 3D-Printed Peptide Drug Delivery Systems, Semi-Solid Extrusion (SSE) 3Khatiso ea D e thusa ho etsoa ha liforomo tsa litekanyetso tse tiileng tsa molomo tse nang le li-geometri tse thata tsa core-shell:
- Ea mantlha: Analogue ea Lipidated GLP-1 e kopantsoe hammoho le li-permeation enhancers (mohlala, Sodium Caprate / KHOTSO).
- Khetla: 3D-printed enteric polymer network (Eudragit L100 / HPMC-AS) e lulang e sa qhibilihe ho pH ea ka mpeng, ho qhibiliha ka potlako feela ha u fihla duodenum ($\mongolo{pH } > 6.0$).
$$\mongolo{Sekhahla sa ho Felloa } \letsetsoa(\frac{dM}{dt}\hantle) = \frac{A \cdot D \cdot (C_s – C_b)}{h}$$
3D mekhabiso ea khatiso (nozzle diameter $200-400\text{ }\mu\text{m}$, extrusion pressure $2.0-4.5\text{ bar}$, temperature $25^\circ\text{C} – 35^\circ\text{C}$) lumella mokhoa o nepahetseng oa geometry oa sebaka ntle le ho senyeha ha mocheso oa conjugated peptide API.
2. Microfluidic Core-Shell Extrusion for Subcutaneous Depots
Ho nka sebaka sa liente tsa subcutaneous khafetsa, mekhoa e tsoelang pele ea khatiso ea 3D microfluidic e etsa bioerodible Poly(lactic-co-glycolic acid) (PLGA) kapa Polycaprolactone (PCL) li-micro-implants.
Ka ho laola kinetics ea ho senyeha ha polymer ($\mongolo{MOTSAMAI:GA}$ karolelano $50:50 \motsu 75:25$), Li-profiles tsa ho lokolla li ka etsoa ho bonts'a phallo ea li-zero 30 ho 90 matsatsi, ho boloka mahloriso a kamehla a kalafo ea plasma ($C_{ss}$) ka har'a fensetere ea phekolo ($C_{min} < C_{ss} < C_{max}$).
Ho itokisa ho Laola & ICH Quality Compliance
Mananeo a fetolelang a tlohile ho tloha nakong ea morao-rao ho ea ho Mokhahlelo 1 liteko tsa tleliniki li tlameha ho hokahanya phallo ea mosebetsi le Lekhotla la Machaba la Harmonization (I) tataiso:
[ICH Q3A(R2)] : Control of Impurities in New Drug Substances (Threshold: > 0.05% ID, > 0.10% Qualification)
[ICH Q3B(R2)] : Control of Impurities in Finished Drug Products
[ICH Q3C(R8)] : Residual Solvent Control (DMF, NMP, DCM, Acetonitrile limits)
[ICH M7] : Assessment and Control of DNA Reactive (Mutagenic) Impurities
Ts'ebetso e Hloekileng Libakeng tse Hloekileng
Hobane post-synthesis terminal sterilization (autoclaving kapa gamma radiation) e baka ho senyeha ha lik'hemik'hale tsa lipid le liketane tsa mahlakoreng a PEG, ho itšehla thajana ha peptide ea ho qetela le lyophilization e tlameha ho etsahala ka har'a e netefalitsoeng Sehlopha 100 setsi sa ho hloekisa ka ho fetisisa. Ho boloka ISO 5 / Maemo a phallo ea laminar ea Kereiti ea A a thibela tšilafalo ea pyrogen le likokoana-hloko nakong ea ho tlatsoa ha tray ea phofo e ngata..
Ho khonahala ho fetolela & 'Mapa oa Ts'ebetsong
Ho tataisa bo-ramahlale ba li-biopharma ka khetho ea tatellano ea pele ho sebetsana le maemo a holimo, matrix ea qeto e ka tlase e kopanya likhokahano tsa bohlokoa tsa phetoho:
| Khetho ea ho Fetola | Molemo oa Pele ($in\text{ }vivo$) | Scale-Up Bottleneck | Leano la ho Fokotsa |
|---|---|---|---|
| Aib8 Phatlalatso | Steric DPP-IV ho hanyetsa | Khokahano e tlase e sebetsa hantle ka lebaka la $N$-terminal tšitiso ea steric | Sebelisa HATU/HOAT kapa ho kopanya habeli mochesong o phahameng ($50^\circ\text{C}$) |
| C18 Diacid Lipidation | E atolositsoe halofo ea bophelo ($>160\mongolo{ h}$), HSA e tlamang | Ho fokola ho qhibiliha, resin gelation, hloekiso e rarahaneng ea HPLC | Bioconjugation ea post-cleavage solution-phase; C4 RP-HPLC at $50^\circ\text{C}$ |
| PEGylation (20-40 kDa) | Ho tlosoa ha renal ea zero | Polydispersity, ho eketseha ha viscosity, ho fokotseha ha bioactivity | Khokahano e khethehileng ea sebaka sa thiol-maleimide; khetho e tiileng ea monodisperse PEG |
| 3D E Hatisitsoeng ka Molomo O Tiile | Boikoetliso bo phahameng ba mokuli | Kutloelo-bohloko ea mocheso nakong ea extrusion, bioavailability e tlase ya molomo | Khatiso ea SSE ea mocheso o tlase; kopanelo le dintlafatso tsa permeation |
Partnering for Translational Success
Ho fetolela li-incretin tse rarahaneng ho hloka tšebetso e kopaneng e kopanyang k'hemistri, analytics, le boikamahanyo ba taolo. Liphetoho tsa MOL (https://molchanges.com/) e fana ka R&D sethala se etselitsoeng boqapi ba biopharma ka ho khetheha:
- E Atolositsoeng Phetoho Suite: Fetile 300 liphetoho tsa lihlopha tse sebetsang, ho kenyelletsa le li-diacids tse tloaelehileng tsa lipid, Lihokelo tsa PEG, li-amino acid tse ngotsoeng ka isotopically, le li-tag tsa fluorescent.
- Sehlopha 100 Lisebelisoa tsa Kamore ea Bohloeki: Tikoloho ea morao-rao e hloekisitsoeng ea tlhahiso e netefatsang endotoxin e tlase haholo ($< 0.01\mongolo{ EU/mg}$) le sterility ea likokoana-hloko.
- Seamless Scalability: Tlhahlobo ea lipatlisiso tsa milligram ho motsoako oa sefofane sa multigram/kilogram ka ho ikatisa ho netefalitsoeng ha batch-to-batch.
- Tiisetso e tiileng ea Boleng ba CoA: HPLC e felletseng, ESI-HRMS, le bohloeki ba chiral bo tsamaisanang le ntho e 'ngoe le e 'ngoe e fanoang.
Memo ea Tekolo ea Setsebi: Na ha joale u ntse u ntlafatsa tatellano ea GLP-1 kapa incretin co-agonist bakeng sa phetolelo ea preclinical? Ikopanye le MOL Liphetoho ho Kopa Tlhahlobo ea Bokhoni ba Bioconjugation le ho lekola tatellano ea tatellano ea hau, lipidation, le litekanyo tsa ho ntlafatsa le sehlopha sa rona sa boenjiniere ba lik'hemik'hale se phahameng.
Litšupiso
- Knudsen, L. B., & Lau, J. (2019). Ho sibolloa le Nts'etsopele ea Liraglutide le Semaglutide. Meeli ho Endocrinology, 10, 155. DOI: 10.3389/sekotjana.2019.00155 | PMID: 31024456 | Tlhahlobo ea Katoloso ea Halofo ea Bophelo
- Prada Brichtova, E., le al. (2024). Phello ea Lipidation ho Sebopeho, Oligomerization, le Aggregation ea Glucagon-joaloka Peptide 1. ACS Bioconjugate Chemistry, 35(4), 484-495. DOI: 10.1021/acs.bioconjchem.4c00012 | PMC: PMC10959496
- Setsi sa Tsebo sa Bachem. (2024). Tlhokahalo ea GLP-1: Se Bolelang ho Baetsi ba Peptide ea Liindasteri. Bachem Industrial Whitepaper
- Mokhatlo oa Batsoali oa Lithethefatsi (PDA). (2025). Lits'oants'o tse Senyehileng tse Bopang Sebaka sa GLP-1: SPPS-to-LPPS Hybrid Synthesis. Sengoloa sa Lengolo la PDA. PDA Phatlalatso Portal
- Zhang, Y., le al. (2025). Ho theha Phatlalatso ea GLP-1: Maikutlo a Sebopeho le Mekhoa ea 3D ea Moetso oa Khatiso bakeng sa Phekolo e Atlehileng.. Litlaleho tsa Mahlale a Tlhaho, 10, 397. DOI: 10.1038/s41598-025-00397-4
- Lekhotla la Machaba la Harmonization (I). (2023). Ke Q3A(R2): Litšila Tse Ncha tsa Lithethefatsi & Ke Q3C(R8): Kakaretso ea Phethahatso ea Maintenance bakeng sa Litaelo tsa Litharollo tsa Masala. Setsi sa Meriana sa Europe (EMA) / US FDA Harmonised Guidelines.
